When: Confirmed close below $140.15 with expanding volume and still-negative MACD histogram

Then: Trim existing MRK exposure toward $139.50 (50 SMA region)

When: At spot

Then: Do not initiate new longs

Trim into rallies; wait for entry zone at $130-$135; do not initiate new longs at spot

• Short-term technicals showing distribution: 16-session negative MACD histogram, bearish RSI divergence from August 19 peak of 83.21, ATR compression after volatility spike, lower highs since August 25
• Net debt has doubled from $24B to $47B in 18 months following $14.6B in H1 2026 acquisitions
• Goodwill and intangibles total $46.6B (36% of total assets) creating M&A execution and potential write-off risk
• Q1 and Q2 2026 GAAP earnings driven negative by in-process R&D charges, creating 118x TTM PE distortion
• Keytruda patent cliff in 2028 creates known terminal event for 75% gross margin franchise facing IRA and MFN pricing pressure
• Aggressive entry at 145-147 provides only 1.5-3% downside buffer against 4-7% upside to prior high — unfavorable risk-reward
• MRK issued $5.95B in new long-term debt in Q2 2026 alone; $54B debt stack faces higher refinancing costs in elevated rate environment
• Peer multiple comparison (MRK 15.6x vs LLY 33x) is inappropriate — LLY's premium reflects GLP-1 growth MRK cannot replicate
• I-DXd FDA withdrawal represents competitive loss in ADC space, not merely a cost-saving measure as characterized by aggressive analyst
• Trading at 52-week highs into stretched multiple without margin of safety is not professional risk management

→ vs aggressive: The 200 SMA/50 SMA 'coiled spring' argument ignores 16 sessions of negative MACD momentum and RSI divergence — cherry-picking long-term indicators while dismissing short-term distribution signals is selection bias, not analysis

→ vs aggressive: The 'miss the move' argument is unfalsifiable — if MRK goes to 165, I missed it; if it pulls back to 132, I should have acted sooner; there is no version where patience is vindicated in the moment, which is exactly why patience is difficult and correct

→ vs aggressive: M&A 'firepower' of $14.6B has doubled net debt to $47B and created $46.6B in goodwill/intangibles — treating every acquisition dollar as value-creating ignores integration risk, IPR&D write-offs, and the fact that Q1/Q2 2026 charges suggest market skepticism of deal payoffs

→ vs aggressive: LLY 33x vs MRK 15.6x comparison is invalid — LLY's multiple reflects GLP-1-driven growth that MRK will never have; MRK's compression rationally prices Keytruda concentration and the 2028 patent cliff

→ vs aggressive: I-DXd withdrawal is a competitive loss in fast-moving ADC space, not responsible portfolio management — BioPharma Dive explicitly states it 'erases an edge over multiple fast-moving competitors'; absence of one-day price reaction does not equal absence of execution risk

→ vs aggressive: Zero retail Reddit chatter is not evidence of institutional accumulation — it could mean no one cares about a defensive name at fair value or that retail has moved to AI stocks; constructing bullish narratives from absence of data is motivated reasoning

→ vs aggressive: 'Higher for longer' rate argument ignores MRK's $5.95B Q2 2026 debt issuance and $54B debt stack — elevated rates increase refinancing costs and debt service on the M&A program itself, conflating equity yield story with corporate balance sheet reality

Hold with conditional buy triggers; do not chase at $148.69, do not wait for $130; instead set first trigger at $142-$145 pullback zone (1/3 position) and second trigger at $155.50 breakout (add 1/3), with final 1/3 reserved for deeper pullback to $140.15 or breakout above $165.

• Long-term golden cross regime confirmed: 200 SMA at 120.47, 50 SMA at 140.15 and rising, price 23% above long-term average
• Distribution signatures present: 16-session negative MACD histogram, lower highs since August 25, RSI rolled from 83 to 57
• Net debt doubled from $24B to $47B in 18 months; goodwill and intangibles at $46.6B (36% of total assets)
• MRK issued $5.95B in new long-term debt in Q2 2026 alone
• $14.6B in H1 2026 acquisitions deployed against patent cliff
• $7B in annual excess free cash flow after dividend
• Keytruda faces patent cliff in approximately 18 months with $30B-plus revenue at structural risk
• I-DXd filing withdrawal represents competitive loss in ADC space
• Conservative pipeline estimate of $5-$8B 2028 contribution deemed more intellectually honest than aggressive $12-$15B scenario
• Welireg and Winrevair identified as real pipeline catalysts
• MRK trades at 17x forward earnings; not comparable to LLY's 33x due to different growth profiles
• Beta of 0.226 means MRK moves about one-quarter as much as the S&P 500
• Stop level at $139.50 (just below 50 SMA at $140.15), representing approximately 6% downside from spot
• Position size calibrated to 1.5 ATR of risk (~$5.27 from current levels)
• Current price at $148.69 at upper end of 30-day range
• Lower Bollinger band at $142.48; recent swing low at $142.84

→ vs aggressive: Called the consolidation a 'coiled spring' which is hopeful, not analytical—a stock that paused at 52-week high with negative MACD histogram and lower highs is digesting, not coiling; resolution can go either direction

→ vs aggressive: Peer multiple comparison (MRK at 15.6x vs LLY at 33x) is a category error; LLY trades at premium for GLP-1 multi-year growth while MRK trades at discount for imminent patent cliff; the gap is correct pricing, not mispricing

→ vs aggressive: Pipeline trajectory argument ($12-$15B) lacks scenario analysis or probability weighting; comparing optimistic scenario to bear's base case is not a fair comparison

→ vs aggressive: Recommending initiating at $148.69 at upper end of 30-day range with negative MACD histogram and into 17x forward multiple with limited room for execution missteps

→ vs conservative: Entry strategy demanding $130-$135 (7-12% pullback) is unrealistic for a 0.226 beta name; would require market-wide correction or company-specific catastrophe; this 'preference' doesn't override expected value calculations

→ vs conservative: Management deployment ($14.6B acquisitions, $7B excess FCF) shows management sees the cliff as addressable; IPR&D write-offs represent accounting treatment for early-stage biotech optionality, not evidence of value destruction

→ vs conservative: Telling existing holders to trim into rallies at $152-$154 is selling into demand, not supply; breakout traders pile in at those levels and the math is bad

→ vs conservative: I-DXd withdrawal framing as 'opportunity cost' is correct but overreach to speculate the market will absorb this gradually as pipeline execution disappoints is not fact about current setup